TY - JOUR
T1 - Newborn Screening for Primary Congenital Hypothyroidism: Estimating Test Performance at Different TSH Thresholds
AU - Knowles, Rachel L
AU - Oerton, Juliet
AU - Cheetham, Timothy
AU - Butler, Gary
AU - Cavanagh, Christine
AU - Tetlow, Lesley
AU - Dezateux, Carol
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Context
Active surveillance of primary congenital hypothyroidism (CH) in a multiethnic population with established newborn bloodspot screening.
Objective
To estimate performance of newborn screening for CH at different test thresholds and calculate incidence of primary CH.
Design
Prospective surveillance from June 2011 to June 2012 with 3-year follow-up of outcomes. Relative likelihood ratios (rLRs) estimated to compare bloodspot TSH test thresholds of 6 mU/L and 8 mU/L, with the nationally recommended standard of 10 mU/L for a presumptive positive result.
Setting
UK National Health Service.
Patients
Clinician notification of children aged <5 years investigated following clinical presentation or presumptive positive screening result.
Main Outcome Measure(s)
Permanent primary CH status determined by clinician report of continuing T4 requirement at 3-year follow-up.
Results
A total of 629 newborns (58.3% girls; 58.7% white ethnicity) were investigated following presumptive positive screening result and 21 children (52.4% girls; 52.4% white) after clinical presentation; 432 remained on treatment at 3-year follow-up. Permanent CH incidence was 5.3 (95% CI, 4.8 to 5.8) per 10,000 infants. With use of locally applied thresholds, sensitivity, specificity, and positive predictive value were 96.76%, 99.97%, and 66.88%, respectively. Compared with a TSH threshold of 10 mU/L, positive rLRs for 8 mU/L and 6 mU/L were 1.20 (95% CI, 0.82 to 1.75) and 0.52 (95% CI, 0.38 to 0.72), and negative rLRs were 0.11 (95% CI, 0.03 to 0.36) and 0.11 (95% CI, 0.06 to 0.20), respectively.
Conclusions
Screening program performance is good, but a TSH threshold of 8 mU/L appears superior to the current national standard (10 mU/L) and requires further evaluation. Further research should explore the implications of transient CH for screening policy.
AB - Context
Active surveillance of primary congenital hypothyroidism (CH) in a multiethnic population with established newborn bloodspot screening.
Objective
To estimate performance of newborn screening for CH at different test thresholds and calculate incidence of primary CH.
Design
Prospective surveillance from June 2011 to June 2012 with 3-year follow-up of outcomes. Relative likelihood ratios (rLRs) estimated to compare bloodspot TSH test thresholds of 6 mU/L and 8 mU/L, with the nationally recommended standard of 10 mU/L for a presumptive positive result.
Setting
UK National Health Service.
Patients
Clinician notification of children aged <5 years investigated following clinical presentation or presumptive positive screening result.
Main Outcome Measure(s)
Permanent primary CH status determined by clinician report of continuing T4 requirement at 3-year follow-up.
Results
A total of 629 newborns (58.3% girls; 58.7% white ethnicity) were investigated following presumptive positive screening result and 21 children (52.4% girls; 52.4% white) after clinical presentation; 432 remained on treatment at 3-year follow-up. Permanent CH incidence was 5.3 (95% CI, 4.8 to 5.8) per 10,000 infants. With use of locally applied thresholds, sensitivity, specificity, and positive predictive value were 96.76%, 99.97%, and 66.88%, respectively. Compared with a TSH threshold of 10 mU/L, positive rLRs for 8 mU/L and 6 mU/L were 1.20 (95% CI, 0.82 to 1.75) and 0.52 (95% CI, 0.38 to 0.72), and negative rLRs were 0.11 (95% CI, 0.03 to 0.36) and 0.11 (95% CI, 0.06 to 0.20), respectively.
Conclusions
Screening program performance is good, but a TSH threshold of 8 mU/L appears superior to the current national standard (10 mU/L) and requires further evaluation. Further research should explore the implications of transient CH for screening policy.
U2 - 10.1210/jc.2018-00658
DO - 10.1210/jc.2018-00658
M3 - Article
SN - 0021-972X
VL - 103
SP - 3720
EP - 3728
JO - The Journal of Clinical Endocrinology & Metabolism
JF - The Journal of Clinical Endocrinology & Metabolism
IS - 10
ER -